Across TCGA pan-cancer cohorts, KRTAP12-4 RNA is linked to patient survival in 11 of 34 cancer types, making it the most broadly survival-associated KRTAP12-4 data layer compared with 2 for mutation status.
The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher KRTAP12-4 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated KRTAP12-4 expression acts as an unfavorable survival marker, although some lineages such as SCLC show a favorable association.
LIHC, SKCM, and THYM are the cancer types where KRTAP12-4 RNA most reproducibly stratifies survival.
RNA survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.